NCT03921411 - A Pharmacokinetics and Safety Study of Nemolizumab in Adolescent Participants With Atopic Dermatitis (AD) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 9, 2019

Primary Completion Date

August 19, 2020

Study Completion Date

August 19, 2020

Conditions

Atopic Dermatitis

Interventions

BIOLOGICAL

Nemolizumab

Participants received subcutaneous (SC) injection of 30 milligram (mg) of Nemolizumab every 4 weeks (Q4W) over a 16-week treatment period, with a loading dose of 60 mg on Day 1.

Trial Locations (10)

23220

Galderma Investigational Site, Richmond

30128

Galderma Investigational Site, Sandy Springs

31904

Galderma Investigational Site, Columbus

32256

Galderma Investigational Site, Jacksonville

33607

Galderma Investigational Site, Tampa

75034

Galderma Investigational Site, Frisco

92708

Galderma Investigational Site, Fountain Valley

94538

Galderma Investigational Site, Fremont

97030

Galderma Investigational Site, Gresham

75230-5806

Galderma Investigational Site, Dallas